Evidence map›Paper›PMID 41284178›Full record

ReviewMedical oncology (Northwood, London, England)2025

The role and application prospects of ANXA1 in gastric cancer cells.

Qinglin Xiong, Jian Wang, Yinglan Liu, Baiqi Wang, Qing Wang, Ailan Cheng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qinglin Xiong *Hunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Cancer Research Institute, Hengyang Medical School, University of South China, No. 28, Changsheng Road, Hengyang, 421001, Hunan Province, China.
Jian Wang *The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Yinglan LiuThe Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Baiqi WangThe Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Qing WangHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Cancer Research Institute, Hengyang Medical School, University of South China, No. 28, Changsheng Road, Hengyang, 421001, Hunan Province, China.
Ailan ChengHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Cancer Research Institute, Hengyang Medical School, University of South China, No. 28, Changsheng Road, Hengyang, 421001, Hunan Province, China. 1996001846@usc.edu.cn.

Funding

Yinglan Liu No.2023SK4052
6 · The paper itself

Abstract

Annexin A1 (ANXA1), a calcium-dependent endogenous immunomodulatory phospholipid-binding protein, is ubiquitously expressed across diverse tissues and cell types. Originally identified as an anti-inflammatory protein, subsequent research revealed that ANXA1 exerts a broader influence on cellular processes beyond inflammation, including tumor cell proliferation, apoptosis, invasion, migration, angiogenesis, and multidrug resistance. In gastric cancer (GC), numerous factors contribute to the complex processes of proliferation, invasion, migration and multidrug resistance among which ANXA1 plays critical roles. Understanding the mechanistic role of ANXA1 in GC is crucial for advancing early diagnosis, treatment strategies, and prognosis assessment. This review summarizes the current knowledge on the physiological functions of ANXA1 in GC pathogenesis and evaluates its potential as both a therapeutic biomarker and a diagnostic biomarker.

Indexed as

Annexin A1Biomarkers, TumorStomach NeoplasmsApoptosisCell MovementCell ProliferationHumansPrognosisAnnexin A1ANXA1 protein, humanBiomarkers, TumorANXA1ChemoresistanceClinical translationGastric cancer

Identifiers

PMID41284178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.